Chimeric anti-tenascin antibody 81C6: Increased tumor localization compared with its murine parent

Michael R. Zalutsky, Gary E. Archer, Pradeep K. Garg, Surinder K. Batra, Darell D. Bigner

Research output: Contribution to journalArticle

22 Scopus citations


When labeled using the Iodogen method, a chimeric antibody composed of the human IgG2 constant region and the variable regions of murine anti tenascin 81C6 exhibited superior uptake in human glioma xenografts compared with its murine parent. In the current study, three paired label experiments were performed in athymic mice with subcutaneous D-54 MG human glioma xenografts to evaluate further the properties of radioiodinated chimeric 81C6. These studies demonstrated that (a) the enhanced tumor uptake of chimeric 81C6 is specific; (b) when labeling was performed using N-succinimidyl 3-iodobenzoate, chimeric 81C6 again showed preferential accumulation in tumor compared with murine 81C6; and (c) the tumor uptake advantage observed previously with murine 81C6 for N-succinimidyl 3-iodobenzoate compared with Iodogen labeling did not occur with chimeric 81C6.

Original languageEnglish (US)
Pages (from-to)449-458
Number of pages10
JournalNuclear Medicine and Biology
Issue number4
StatePublished - May 1996



  • Chimeric antibody
  • Glioma
  • Monoclonal antibody
  • Radioiodination

ASJC Scopus subject areas

  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this